Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- LDP Health Panel Holds Drug Pricing Hearing with Doctor, Pharmacist Groups
April 28, 2017
- Ad-Hoc Generic Prices for “Off-Year” Revisions Acceptable: Chuikyo Bill Payer Reps
April 27, 2017
- JMA’s Nakagawa Says MHLW Should Fuel Generic Industry Realignment: Chuikyo
April 27, 2017
- Savings from Generic Use Increase Sharply from FY2013 through FY2015: MHLW Estimate
April 27, 2017
- New LDP Lawmaker Group on Generics to Draw Up Proposal for 2017 Fiscal Blueprint
April 26, 2017
- Non-Partisan Lawmaker Group on Cooperation with WHO Set Up, Eyeing Asia Pacific Region Congress in Japan this Summer
April 26, 2017
- Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
- Drug Pricing Is Internal Affairs Not Subject to Bilateral Talks: Minister
April 25, 2017
- Apply GDP to Cash-and-Carry Dealers Too: MHLW Panel Members
April 24, 2017
- MHLW Committee Backs Approval of Mundipharma’s PTCL Med Pralatrexate
April 24, 2017
- Commerce Secretary Ross Made No Specific Demand on Drug Pricing: Shiozaki
April 24, 2017
- Negative Opinions Exist for Use of Cost Effective Assessments in Drug Listing: MHLW Official
April 24, 2017
- Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
- MHLW Panel OKs 2-Year Extension of Reexamination Period for E Keppra due to Development of Dosage for Children Younger than 4
April 24, 2017
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- MOF Puts June-End Generic Share at Around 65%, Just Shy of Mid-Year 70% Target
April 21, 2017
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…